Xeris hauls $55M in new funding to bring glucagon pen to market
Chicago’s Xeris Pharmaceuticals has $55 million in new money to work as the company preps to take its lead investigational product – a glucagon rescue pen for diabetics – to the market.
The funding mainly comes from a $45 million loan from Silicon Valley Bank and Oxford Finance, with the remaining $10 million coming by way of a Series C equity round. The C backers include Merieux Développement, which led the round, and Wild Basin Investments.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
